Brian Mendelsohn
Independent Consultant Independent Consultant
Brian A. Mendelsohn, Principal at MBC Consulting, is an accomplished researcher in the field of antibody drug conjugates. Brian started exploring ADCs in 2000 with Seattle Genetics, where he first synthesized the MMAE and MMAF payloads. Working across drug-development from discovery to manufacturing, he developed novel ADCs, ADC linker-payloads and conjugation technologies at Agensys, Ajinomoto Bio-Pharma Services, and Exelixis. Brian has published 42 scientific manuscripts and received accolades for contributions to the field of ADCs: Heroes of Chemistry by the American Chemical Society for developing Adcetris® in 2018, and the George R Pettit Individual Input to the Field for 2023.
Seminars
Understanding the advancements at the forefront of conjugation chemistries are vital to optimize ADC design, DAR and therapeutic properties from the get-go.
Join this workshop to secure your understanding of fundamental principles of ADC conjugation and assess the pros and cons of next-generation technologies.
Workshop Highlights Include:
- Delving into case studies of stochastic and site-specific conjugation to understand ADC design principles and connection to therapeutic profile
- Exploring state-of-the-art and niche conjugation approaches across click chemistry, enzymatic, chemical and antibody engineering conjugation to push the boundaries of novel ADC design
- Breaking down dual payload conjugation strategies as the field increasingly focuses on multi-mechanism approaches
- Beyond ADCs: Understanding additional nuances beyond traditional conjugation across AOCs, PDCs and beyond
